Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD.
COPD is associated with increased arterial stiffness which may in part explain the cardiovascular morbidity observed in the disease. A causal relationship between arterial stiffness and cardiovascular events has not been established, though their strong association raises the possibility that therapies that reduce arterial stiffness may improve cardiovascular outcomes. Prior studies suggest that fluticasone propionate/salmeterol (FSC) may improve cardiovascular outcomes in COPD and we hypothesized that FSC would reduce arterial stiffness in these patients.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Version: za2963e q8za8 q8zb9 q8zc9 q8zd6 q8ze6 q8zf0 q8zgf